KR20200003933A - 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법 - Google Patents

알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법 Download PDF

Info

Publication number
KR20200003933A
KR20200003933A KR1020197038395A KR20197038395A KR20200003933A KR 20200003933 A KR20200003933 A KR 20200003933A KR 1020197038395 A KR1020197038395 A KR 1020197038395A KR 20197038395 A KR20197038395 A KR 20197038395A KR 20200003933 A KR20200003933 A KR 20200003933A
Authority
KR
South Korea
Prior art keywords
compound
cancer
alkyl
compounds
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197038395A
Other languages
English (en)
Korean (ko)
Inventor
왕 센
아이민 장
잭 마웅
샤오링 쩡
Original Assignee
뉴젠 세러퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴젠 세러퓨틱스 인코포레이티드 filed Critical 뉴젠 세러퓨틱스 인코포레이티드
Publication of KR20200003933A publication Critical patent/KR20200003933A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197038395A 2011-03-04 2012-03-02 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법 Ceased KR20200003933A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449088P 2011-03-04 2011-03-04
US61/449,088 2011-03-04
PCT/US2012/027614 WO2012122058A2 (en) 2011-03-04 2012-03-02 Alkyne substituted quinazoline compound and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137026199A Division KR102061743B1 (ko) 2011-03-04 2012-03-02 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217010767A Division KR20210043016A (ko) 2011-03-04 2012-03-02 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법

Publications (1)

Publication Number Publication Date
KR20200003933A true KR20200003933A (ko) 2020-01-10

Family

ID=46798728

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197038395A Ceased KR20200003933A (ko) 2011-03-04 2012-03-02 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
KR1020137026199A Active KR102061743B1 (ko) 2011-03-04 2012-03-02 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
KR1020217010767A Ceased KR20210043016A (ko) 2011-03-04 2012-03-02 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
KR1020227006071A Ceased KR20220031732A (ko) 2011-03-04 2012-03-02 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020137026199A Active KR102061743B1 (ko) 2011-03-04 2012-03-02 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
KR1020217010767A Ceased KR20210043016A (ko) 2011-03-04 2012-03-02 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
KR1020227006071A Ceased KR20220031732A (ko) 2011-03-04 2012-03-02 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법

Country Status (14)

Country Link
US (5) US9090588B2 (https=)
EP (1) EP2680850B1 (https=)
JP (1) JP6006242B2 (https=)
KR (4) KR20200003933A (https=)
CN (1) CN103998040B (https=)
AU (3) AU2012225693A1 (https=)
BR (1) BR112013022552B1 (https=)
CA (1) CA2828713C (https=)
IL (1) IL228072A (https=)
MX (1) MX344302B (https=)
RU (1) RU2013144571A (https=)
SG (3) SG193291A1 (https=)
TW (1) TWI617556B (https=)
WO (1) WO2012122058A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122058A2 (en) 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
JP6437820B2 (ja) * 2011-07-27 2018-12-12 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド キナゾリン誘導体、その製造方法、中間体、組成物及びその適用
TWI609012B (zh) 2013-04-28 2017-12-21 廣東東陽光藥業有限公司 氨基喹唑啉類衍生物及其鹽和使用方法
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
CN103254156B (zh) * 2013-05-10 2015-08-26 苏州明锐医药科技有限公司 阿法替尼中间体的制备方法
SG11201805286RA (en) * 2015-12-24 2018-07-30 Kyowa Hakko Kirin Co Ltd α,β-UNSATURATED AMIDE COMPOUND
DE102016224889B4 (de) * 2016-12-14 2019-11-07 Airbus Defence and Space GmbH Verfahren zur Vorbeugung einer Ablösung einer Fluidströmung, Strömungskörpersystem und Luftfahrzeug
US11083492B2 (en) * 2018-06-06 2021-08-10 Lifetech Scientific (Shenzhen) Co., Ltd Method for implanting an interventional medical device
US10973321B2 (en) 2018-09-04 2021-04-13 Steelcase Inc. Workspace system and components and method for the use thereof
JP2022502495A (ja) 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用
AU2020328598A1 (en) * 2019-08-15 2022-03-03 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2021209039A1 (zh) * 2020-04-17 2021-10-21 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
CN113527215B (zh) * 2020-04-17 2023-12-05 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
US20240075042A1 (en) * 2020-11-02 2024-03-07 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
CN120769850A (zh) * 2023-03-02 2025-10-10 江苏康缘药业股份有限公司 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062881A (en) 1974-07-26 1977-12-13 Cincinnati Milacron Chemicals, Inc. Sulfide containing tin stabilizers
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
EP0326307B1 (en) 1988-01-23 1994-08-17 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
US5053227A (en) 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
JP3089901B2 (ja) 1993-07-20 2000-09-18 株式会社豊田自動織機製作所 クラッチレス圧縮機における動力伝達構造
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9405355D0 (en) 1994-03-18 1994-05-04 Lucas Ind Plc Vibrating element transducer
AU5108196A (en) 1995-03-20 1996-10-08 Dr. Karl Thomae Gmbh Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EP0770080B1 (en) 1995-05-12 1999-07-14 Neurogen Corporation Novel deazapurine derivatives; a new class of crf1 specific ligands
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222545A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
JP3290666B2 (ja) 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
WO1997038973A1 (en) 1996-04-16 1997-10-23 Ube Industries, Ltd. Hydrazine compounds, process for the preparation thereof, and insecticides for agricultural and horticultural use
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
EP1100788B1 (en) 1998-07-30 2005-11-09 Wyeth Substituted quinazoline derivatives
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
AU2001273071B2 (en) 2000-06-30 2005-09-08 Glaxo Group Limited Quinazoline ditosylate salt compounds
CN1276754C (zh) 2000-10-27 2006-09-27 诺瓦提斯公司 胃肠基质肿瘤的治疗
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2442742A1 (en) 2001-02-21 2002-08-29 Mitsubishi Pharma Corporation Quinazoline derivatives
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
JP4353903B2 (ja) 2005-01-07 2009-10-28 東京エレクトロン株式会社 クラスタツールの処理システム
CN101203494A (zh) * 2005-05-25 2008-06-18 惠氏公司 合成经取代3-氰基喹啉和其中间物的方法
JP5688877B2 (ja) * 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
WO2007085638A1 (en) 2006-01-26 2007-08-02 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
CN100345856C (zh) 2006-03-10 2007-10-31 武汉化工学院 一种制备葡萄糖醛酸内酯的酯化及结晶工艺方法
AU2007296746B2 (en) 2006-09-11 2012-07-05 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008119663A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN105037333A (zh) 2009-12-21 2015-11-11 张强 新的喹唑啉衍生物
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
WO2012122058A2 (en) 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途

Also Published As

Publication number Publication date
SG10201601711SA (en) 2016-04-28
CA2828713A1 (en) 2012-09-13
WO2012122058A2 (en) 2012-09-13
SG10201913982WA (en) 2020-03-30
US20190382382A1 (en) 2019-12-19
US20160031860A1 (en) 2016-02-04
US20180093975A1 (en) 2018-04-05
JP2014518544A (ja) 2014-07-31
RU2013144571A (ru) 2015-04-10
BR112013022552A2 (pt) 2016-12-06
EP2680850A2 (en) 2014-01-08
KR20210043016A (ko) 2021-04-20
TWI617556B (zh) 2018-03-11
CN103998040A (zh) 2014-08-20
EP2680850B1 (en) 2018-05-23
WO2012122058A3 (en) 2014-04-24
EP2680850A4 (en) 2015-01-28
AU2018267622B2 (en) 2020-05-14
BR112013022552B1 (pt) 2021-11-23
KR102061743B1 (ko) 2020-01-03
SG193291A1 (en) 2013-10-30
KR20220031732A (ko) 2022-03-11
US20140128417A1 (en) 2014-05-08
TW201249835A (en) 2012-12-16
US9090588B2 (en) 2015-07-28
CA2828713C (en) 2022-08-16
AU2017200984A1 (en) 2017-03-02
IL228072A0 (en) 2013-09-30
KR20140020955A (ko) 2014-02-19
MX344302B (es) 2016-12-13
AU2018267622A1 (en) 2018-12-13
US20210047303A1 (en) 2021-02-18
IL228072A (en) 2016-08-31
MX2013010016A (es) 2013-11-20
AU2012225693A1 (en) 2013-09-19
CN103998040B (zh) 2017-03-29
JP6006242B2 (ja) 2016-10-12
US11524956B2 (en) 2022-12-13

Similar Documents

Publication Publication Date Title
KR102061743B1 (ko) 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
JP5721709B2 (ja) リンを含むキナゾリン化合物および使用方法
EP3749646B1 (en) Heteroaryl compounds as kinase inhibitor
US9187459B2 (en) Quinazoline-7-ether compounds and methods of use
TW201002694A (en) Quinazoline derivatives
IL298132A (en) Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one
CN103717590B (zh) 喹唑啉-7-醚化合物及使用方法
JPWO2018159613A1 (ja) ピラゾロ［３，４−ｄ］ピリミジン化合物を用いた抗腫瘍効果増強剤
JP2020524659A (ja) 化合物
EA045568B1 (ru) Солевые и кристаллические формы 4-амино-5-(6-(4-метилпиперазин-1-ил)-1н-бензо[d]имидазол-2-ил)тиено[2,3-в]пиридин-6(7н)-она

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191226

Application number text: 1020137026199

Filing date: 20131004

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200123

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200211

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210111

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200211

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210412

Application number text: 1020137026199

Filing date: 20131004

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210412

WITB Written withdrawal of application